News Verily plans digital ophthalmology joint venture with Santen Verily is planning a digital ophthalmology joint venture with Japan’s specialist in the field, Santen.
News Oxford Biomedica signs ophthalmology R&D deal with Santen UK biotech Oxford Biomedica and Japan’s Santen have begun an option and licence agreement to research and develop gene therapy products for an inherited retinal disease.
Partner Content Partner Content Queen's University Belfast and Santen to Present Opening Key... Ophthalmic Drugs Conference London
Events Partner Content Ophthalmic Drugs - Europe's Leading Ophthalmic Conference Ophthalmic Drugs Conference
Partner Content Partner Content Boehringer Ingelheim, Novaliq, Santen, Shire, at Europe's Le... SMi’s Leading Ophthalmic Conference
Oncology Treating primary bone cancer: The potential of listeria-base... In a new pharmaphorum podcast, Paul Romness, president and CEO of OS Therapies, discusses the company's work in osteosarcoma.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
